The global blood plasma derivatives market size was valued at USD 48.27 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 75.9 Billion by 2033, exhibiting a CAGR of 5.2% from 2025-2033. North America currently dominates the market, holding a market share of over 48.9% in 2024. The rising chronic disease prevalence, advanced plasma collection infrastructure, technological innovations, growing geriatric population, and expanding therapeutic applications are some of the factors driving the market growth in this region.
Blood plasma derivatives are concentrates of specific proteins prepared from plasma that are obtained through fractionation process. Factor VIII, immunoglobulin, albumin, hyperimmune globulin, factor IX and fresh frozen are some of the common blood plasma derivatives. They are rich in proteins, minerals, salts, hormones, vitamins and protease inhibitors, due to which they are widely used to kill viruses that cause hepatitis B, hemophilia A, bleeding disorders, immunodeficiency, hepatitis C, hypogammaglobulinemia, hemophilia B and human immunodeficiency virus (HIV). Apart from this, blood plasma derivatives assist in enhancing nutrition, controlling body temperature and coagulation of blood, maintaining osmotic pressure, enhancing respiration and excretion, and regulating acid-base balance. Blood plasma derivatives are commonly stored at hospitals, clinics, diagnostic centers and blood transfusion centers.
Blood Plasma Derivatives Market Trends:
The increasing geriatric population that are more susceptible to developing infectious diseases are creating a positive outlook for the market. Blood plasma contains immunoglobulins that play an important role in the development of immunity and maintain the osmotic pressure in blood vessels, which further prevents the onset immunodeficiency disorders and hemophilia. Moreover, the widespread product adoption to treat coronavirus disease (COVID-19) patients by convalescent plasma treatment is favoring the market growth. Additionally, various technological innovations in the fractionation process that aids in separating protein concentrates and various components of blood plasma for clinical purposes are providing a considerable boost to the market growth. In line with this, the development of advanced preservation methods, along with the significant improvements in encased procedures for developing targeted therapeutic products are further augmenting the market growth. Other factors, including significant growth in the healthcare industry, increasing awareness regarding blood and plasma donation and the implementation of various government initiatives to promote blood donation camps, are anticipated to drive the market further toward growth.
Key Market Segmentation:
Breakup by Type:
Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others
Breakup by Application:
Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand's Disease
Others
Breakup by End User:
Hospitals
Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Key Questions Answered in This Report
1.What are blood plasma derivatives?
2.How big is the blood plasma derivatives market?
3.What is the expected growth rate of the global blood plasma derivatives market during 2025-2033?
4.What are the key factors driving the global blood plasma derivatives market?
5.What is the leading segment of the global blood plasma derivatives market based on type?
6.What is the leading segment of the global blood plasma derivatives market based on application?
7.What is the leading segment of the global blood plasma derivatives market based on end user?
8.What are the key regions in the global blood plasma derivatives market?
9.Who are the key players/companies in the global blood plasma derivatives market?